Wilmington Savings Fund Society FSB Increases Stake in Zoetis Inc. (NYSE:ZTS)

Wilmington Savings Fund Society FSB raised its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 135.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 43,720 shares of the company’s stock after buying an additional 25,114 shares during the period. Wilmington Savings Fund Society FSB’s holdings in Zoetis were worth $7,123,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of ZTS. State Street Corp boosted its stake in shares of Zoetis by 0.5% during the third quarter. State Street Corp now owns 19,779,344 shares of the company’s stock valued at $3,864,488,000 after purchasing an additional 95,856 shares during the period. Geode Capital Management LLC increased its position in shares of Zoetis by 1.8% in the third quarter. Geode Capital Management LLC now owns 10,427,760 shares of the company’s stock valued at $2,030,813,000 after acquiring an additional 185,364 shares during the period. Mizuho Securities USA LLC boosted its holdings in shares of Zoetis by 13,726.9% during the third quarter. Mizuho Securities USA LLC now owns 4,865,000 shares of the company’s stock worth $950,524,000 after purchasing an additional 4,829,815 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its stake in shares of Zoetis by 5.3% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 3,896,106 shares of the company’s stock worth $761,221,000 after purchasing an additional 194,542 shares during the last quarter. Finally, JPMorgan Chase & Co. raised its position in Zoetis by 10.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 2,916,539 shares of the company’s stock valued at $569,834,000 after purchasing an additional 279,092 shares during the last quarter. 92.80% of the stock is owned by institutional investors.

Zoetis Trading Down 1.6 %

NYSE:ZTS opened at $171.37 on Friday. The stock has a market cap of $77.32 billion, a price-to-earnings ratio of 32.21, a PEG ratio of 2.77 and a beta of 0.90. The company has a quick ratio of 2.27, a current ratio of 3.69 and a debt-to-equity ratio of 1.26. The company’s 50 day moving average price is $169.34 and its 200-day moving average price is $179.28. Zoetis Inc. has a 52 week low of $144.80 and a 52 week high of $200.53.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 3rd. Shareholders of record on Monday, April 21st will be issued a $0.50 dividend. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.17%. The ex-dividend date of this dividend is Monday, April 21st. Zoetis’s payout ratio is 37.59%.

Analysts Set New Price Targets

Several analysts recently weighed in on the stock. Stifel Nicolaus cut their price target on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating on the stock in a report on Tuesday, January 7th. Morgan Stanley reduced their price target on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a research report on Wednesday, January 29th. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research report on Monday, December 2nd. JPMorgan Chase & Co. increased their target price on Zoetis from $225.00 to $230.00 and gave the stock an “overweight” rating in a research report on Friday, October 11th. Finally, UBS Group started coverage on Zoetis in a research report on Monday, December 9th. They set a “neutral” rating and a $196.00 price target on the stock. One investment analyst has rated the stock with a hold rating, ten have issued a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, Zoetis currently has an average rating of “Buy” and an average price target of $215.00.

About Zoetis

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.